PAH Is the Focus of New Clinical Series Using CXA-10 Therapy

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

ph_pha focus

Complexa Inc., a biopharmaceutical company developing therapies to treat fibrosis and inflammation-related diseases, announced the successful completion of a Phase 1 clinical program for its lead drug candidate CXA-10, and the beginning of preparations for Phase 2 clinical trials for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH) in 2016.

The announcement builds on a growing trend in PAH drug development that targets inflammation. Data on the cardiovascular and renal benefits obtained by administering CXA-10 to patients was recently presented at the 2015 American Society of Nephrology’s Kidney Week.

 

Read more: http://bit.ly/1XaD3Vu

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

CXA-10, PAH, pulmonary arterial hypertension (PAH), Pulmonary hypertension (PHT)

Recent Posts


Recommended reading